The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
The Evolving Role of Histology in the Management of Advanced Non–Small-Cell Lung Cancer
Abstract
Until recently, non–small-cell lung cancer (NSCLC) was treated as a single disease despite recognition of its histologic and molecular heterogeneity. Recent clinical trials, however, demonstrate that histology is an important factor for individualizing treatment, based on either safety or efficacy outcomes. For example, the labeling of the licensed agents bevacizumab and pemetrexed is restricted to patients with nonsquamous cell NSCLC. For bevacizumab, this restriction is due to an apparent association between squamous cell histology and severe pulmonary hemorrhage, whereas for pemetrexed, superior treatment effects have been observed in patients with nonsquamous cell histology. Given fewer agents are both active and tolerable in patients with squamous cell carcinoma compared with adenocarcinoma, and the nature of this particular phenotype of NSCLC, new drugs are needed for this histology. In this new histology-based treatment era, questions persist. Can pathology accurately distinguish the histologic subtypes of NSCLC? Can we use cytologic diagnosis? In the future, will molecular profiling of tumors trump histologic analysis? Herein we describe how therapy for NSCLC is evolving on the basis of a better understanding of molecular mechanisms underlying NSCLC histologic heterogeneity and tumorigenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Karp, D. D., Paz-Ares, L. G., Novello, S., Haluska, P., Garland, L., Cardenal, F., Blakely, L. J., Eisenberg, P. D., Langer, C. J., Blumenschein, G., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.9331 · Cited by 260
Self-citationRetractedGefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
Self-citationWilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J.-Y., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,874
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517
Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Herbst, R. S., Heymach, J. V., & Lippman, S. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0802714 · Cited by 2,389
Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
Thatcher, N., Chang, A., Parikh, P., Rodrigues Pereira, J., Ciuleanu, T., von Pawel, J., Thongprasert, S., Tan, E. H., Pemberton, K., Archer, V., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67625-8 · Cited by 2,079
Mendel, D. B., Laird, A., Xin, X., Louie, S. G., Christensen, J. G., Li, G., Schreck, R., Abrams, T. J., Ngai, T. J., Lee, L. B., et al. (2003) · PubMed · Cited by 1,961
Johnson, D. H., Fehrenbacher, L., Novotny, W. F., Herbst, R. S., Nemunaitis, J. J., Jablons, D. M., Langer, C. J., DeVore, R. F., Gaudreault, J., Damico, L. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.022 · Cited by 1,937
Self-citationClinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
Shaw, A. T., Yeap, B. Y., Mino-Kenudson, M., Digumarthy, S. R., Costa, D. B., Heist, R. S., Solomon, B., Stubbs, H., Admane, S., McDermott, U., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.6993 · Cited by 1,870
Fukuoka, M., Wu, Y.-L., Thongprasert, S., Sunpaweravong, P., Leong, S.-S., Sriuranpong, V., Chao, T.-Y., Nakagawa, K., Chu, D.-T., Saijo, N., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.4235 · Cited by 1,581
Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., Leighl, N., Mezger, J., Archer, V., Moore, N., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5466 · Cited by 1,505
Tumor invasion and metastases--role of the extracellular matrix: Rhoads Memorial Award lecture.
Liotta, L. A. (1986) · PubMed · Cited by 1,400
Pirker, R., Pereira, J. R., Szczesna, A., von Pawel, J., Krzakowski, M., Ramlau, R., Vynnychenko, I., Park, K., Yu, C.-T., Ganul, V., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60569-9 · Cited by 1,351
Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53
Livingstone, L. R., White, A., Sprouse, J., Livanos, E., Jacks, T., & Tlsty, T. D. (1992) · Cell · doi:10.1016/0092-8674(92)90243-6 · Cited by 1,332
Kim, E. S., Hirsh, V., Mok, T., Socinski, M. A., Gervais, R., Wu, Y.-L., Li, L.-Y., Watkins, C. L., Sellers, M. V., Lowe, E. S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61758-4 · Cited by 1,242
Cappuzzo, F., Ciuleanu, T., Stelmakh, L., Cicenas, S., Szczésna, A., Juhász, E., Esteban, E., Molinier, O., Brugger, W., Melezínek, I., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70112-1 · Cited by 1,186
Ciuleanu, T., Brodowicz, T., Zielinski, C., Kim, J. H., Krzakowski, M., Laack, E., Wu, Y.-L., Bover, I., Begbie, S., Tzekova, V., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61497-5 · Cited by 1,111
Characterizing the cancer genome in lung adenocarcinoma
Weir, B. A., Woo, M. S., Getz, G., Perner, S., Ding, L., Beroukhim, R., Lin, W. M., Province, M. A., Kraja, A., Johnson, L. A., et al. (2007) · Nature · doi:10.1038/nature06358 · Cited by 1,105
The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights
Samani, A. A., Yakar, S., LeRoith, D., & Brodt, P. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0001 · Cited by 1,005
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
O'Farrell, A.-M., Abrams, T. J., Yuen, H. A., Ngai, T. J., Louie, S. G., Yee, K. W. H., Wong, L. M., Hong, W., Lee, L. B., Town, A., et al. (2003) · Blood · doi:10.1182/blood-2002-07-2307 · Cited by 864
The International Epidemiology of Lung Cancer: Geographical Distribution and Secular Trends
Youlden, D. R., Cramb, S. M., & Baade, P. D. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31818020eb · Cited by 812
(1986) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60034-2 · Cited by 800
Linardou, H., Dahabreh, I. J., Kanaloupiti, D., Siannis, F., Bafaloukos, D., Kosmidis, P., Papadimitriou, C. A., & Murray, S. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70206-7 · Cited by 739
Scagliotti, G., Hanna, N., Fossella, F., Sugarman, K., Blatter, J., Peterson, P., Simms, L., & Shepherd, F. A. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0232 · Cited by 690
Abrams, T. J., Lee, L. B., Murray, L. J., Pryer, N., & Cherrington, J. M. (2003) · PubMed · Cited by 685
The 2004 World Health Organization classification of lung tumors
Beasley, M. B., Brambilla, E., & Travis, W. D. (2005) · Seminars in Roentgenology · doi:10.1053/j.ro.2005.01.001 · Cited by 564
Self-citationShih, Y.-C. T., Xu, Y., Cormier, J. N., Giordano, S., Ridner, S. H., Buchholz, T. A., Perkins, G. H., & Elting, L. S. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.3517 · Cited by 489
O'Donnell, A., Faivre, S., Burris, H. A., Rea, D., Papadimitrakopoulou, V., Shand, N., Lane, H. A., Hazell, K., Zoellner, U., Kovarik, J. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.0988 · Cited by 479
Epidemiology of Lung Cancer: Looking to the Future
Alberg, A. J., Brock, M. V., & Samet, J. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.462 · Cited by 476
Lynch, T. J., Patel, T., Dreisbach, L., McCleod, M., Heim, W. J., Hermann, R. C., Paschold, E., Iannotti, N. O., Dakhil, S., Gorton, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9618 · Cited by 447
Scagliotti, G., Novello, S., von Pawel, J., Reck, M., Pereira, J. R., Thomas, M., Abrão Miziara, J. E., Balint, B., De Marinis, F., Keller, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.1321 · Cited by 447
Nguyen, K.-S. H., Kobayashi, S., & Costa, D. B. (2009) · Clinical Lung Cancer · doi:10.3816/clc.2009.n.039 · Cited by 437
Lebanony, D., Benjamin, H., Gilad, S., Ezagouri, M., Dov, A., Ashkenazi, K., Gefen, N., Izraeli, S., Rechavi, G., Pass, H., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.4134 · Cited by 408
Wistuba, I. I., Behrens, C., Virmani, A. K., Mele, G. M., Milchgrub, S., Girard, L., Fondon, J. W., Garner, H. R., McKay, B., Latif, F., et al. (2000) · PubMed · Cited by 405
Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis
Kwiatkowski, D. J. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.2.5.446 · Cited by 387
Cohen, B. D., Baker, D. A., Soderstrom, C., Tkalcevic, G., Rossi, A. M., Miller, P. E., Tengowski, M. W., Wang, F., Gualberto, A., Beebe, J. S., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1070 · Cited by 365
Self-citationCeppi, P., Volante, M., Saviozzi, S., Rapa, I., Novello, S., Cambieri, A., Lo Iacono, M., Cappia, S., Papotti, M., & Scagliotti, G. V. (2006) · Cancer · doi:10.1002/cncr.22208 · Cited by 363
Breathnach, O. S., Freidlin, B., Conley, B., Green, M. R., Johnson, D. H., Gandara, D. R., O’Connell, M., Shepherd, F. A., & Johnson, B. E. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1734 · Cited by 354
Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions
Ramalingam, S., & Belani, C. (2008) · The Oncologist · doi:10.1634/theoncologist.13-s1-5 · Cited by 333
Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung Cancer
Socinski, M. A., Novello, S., Brahmer, J. R., Rosell, R., Sanchez, J. M., Belani, C. P., Govindan, R., Atkins, J. N., Gillenwater, H. H., Pallares, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9303 · Cited by 323
Murray, L. J., Abrams, T. J., Long, K. R., Ngai, T. J., Olson, L. M., Hong, W., Keast, P. K., Brassard, J. A., O'Farrell, A. M., Cherrington, J. M., et al. (2003) · Clinical & Experimental Metastasis · doi:10.1023/b:clin.0000006873.65590.68 · Cited by 305
Toyooka, S., Maruyama, R., Toyooka, K. O., McLerran, D., Feng, Z., Fukuyama, Y., Virmani, A. K., Zochbauer‐Muller, S., Tsukuda, K., Sugio, K., et al. (2003) · International Journal of Cancer · doi:10.1002/ijc.10787 · Cited by 288
Grønberg, B. H., Bremnes, R. M., Fløtten, Ø., Amundsen, T., Brunsvig, P. F., Hjelde, H. H., Kaasa, S., von Plessen, C., Stornes, F., Tollåli, T., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.9114 · Cited by 288
Kim, D. W., Jo, Y. S., Jung, H. S., Chung, H. K., Song, J. H., Park, K. C., Park, S. H., Hwang, J. H., Rha, S. Y., Kweon, G. R., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2845 · Cited by 279
Mita, M. M., Mita, A. C., Chu, Q. S., Rowinsky, E. K., Fetterly, G. J., Goldston, M., Patnaik, A., Mathews, L., Ricart, A. D., Mays, T., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.0345 · Cited by 273
Khambata-Ford, S., Harbison, C. T., Hart, L. L., Awad, M., Xu, L.-A., Horak, C. E., Dakhil, S., Hermann, R. C., Lynch, T. J., & Weber, M. R. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.2890 · Cited by 266
Patterns of chromosomal imbalances in adenocarcinoma and squamous cell carcinoma of the lung.
Petersen, I., Bujard, M., Petersen, S., Wolf, G., Goeze, A., Schwendel, A., Langreck, H., Gellert, K., Reichel, M., Just, K., et al. (1997) · PubMed · Cited by 256
Gualberto, A., Aldape, K., Kozakiewicz, K., & Tlsty, T. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.9.5166 · Cited by 237
Self-citationGoss, G. D., Arnold, A., Shepherd, F. A., Dediu, M., Ciuleanu, T.-E., Fenton, D., Zukin, M., Walde, D., Laberge, F., Vincent, M. D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.9427 · Cited by 235
Wistuba, I. I., & Gazdar, A. F. (2006) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.1.110304.100103 · Cited by 234
Accurate Classification of Non–Small Cell Lung Carcinoma Using a Novel MicroRNA-Based Approach
Bishop, J. A., Benjamin, H., Cholakh, H., Chajut, A., Clark, D. P., & Westra, W. H. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2638 · Cited by 223
Hirsch, F. R., Spreafico, A., Novello, S., Wood, M. D., Simms, L., & Papotti, M. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318189f551 · Cited by 220
Finberg, K. E., Sequist, L. V., Joshi, V. A., Muzikansky, A., Miller, J. M., Han, M., Beheshti, J., Chirieac, L. R., Mark, E. J., & Iafrate, A. J. (2007) · The Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2007.060182 · Cited by 214
Blumenschein, G. R., Gatzemeier, U., Fossella, F., Stewart, D. J., Cupit, L., Cihon, F., O'Leary, J., & Reck, M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.0541 · Cited by 205
Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions
Barr, S., Thomson, S., Buck, E., Russo, S., Petti, F., Sujka-Kwok, I., Eyzaguirre, A., Rosenfeld-Franklin, M., Gibson, N. W., Miglarese, M., et al. (2008) · Clinical & Experimental Metastasis · doi:10.1007/s10585-007-9121-7 · Cited by 197
Miller, V. A., Das, A., & Rossi, M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.lba8002 · Cited by 193
Kitamura, H., Kameda, Y., Ito, T., & Hayashi, H. (1999) · American Journal of Clinical Pathology · doi:10.1093/ajcp/111.5.610 · Cited by 186
Giovannetti, E., Mey, V., Nannizzi, S., Pasqualetti, G., Marini, L., Del Tacca, M., & Danesi, R. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.009373 · Cited by 179
Prognostic factors versus predictive factors: Examples from a clinical trial of erlotinib
Clark, G. M. (2007) · Molecular Oncology · doi:10.1016/j.molonc.2007.12.001 · Cited by 151
Worldwide trends in lung cancer pathology
Gabrielson, E. W. (2006) · Respirology · doi:10.1111/j.1440-1843.2006.00909.x · Cited by 145
Early Involvement of the Phosphatidylinositol 3-Kinase/Akt Pathway in Lung Cancer Progression
Massion, P. P., Taflan, P. M., Shyr, Y., Rahman, S. M. J., Yildiz, P., Shakthour, B., Edgerton, M. E., Ninan, M., Andersen, J. J., & Gonzalez, A. L. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-487oc · Cited by 141
Novello, S., Scagliotti, G. V., Rosell, R., Socinski, M. A., Brahmer, J. R., Atkins, J., Pallarés, C., Burgess, R., Tye, L., Selaru, P., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605346 · Cited by 135
Sakuma, Y., Matsukuma, S., Yoshihara, M., Nakamura, Y., Noda, K., Nakayama, H., Kameda, Y., Tsuchiya, E., & Miyagi, Y. (2007) · American Journal of Clinical Pathology · doi:10.1309/wvxfgaflaux48du6 · Cited by 131
Suzuki, M., Shigematsu, H., Iizasa, T., Hiroshima, K., Nakatani, Y., Minna, J. D., Gazdar, A. F., & Fujisawa, T. (2006) · Cancer · doi:10.1002/cncr.21853 · Cited by 127
Jassem, J., Langer, C. J., Karp, D. D., Mok, T. S. K., Benner, R. J., Green, S., Park, K., Novello, S., Strausz, J., & Gualberto, A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.7500 · Cited by 121
Self-citationFukuoka, M., Wu, Y., Thongprasert, S., Yang, J. C., Chu, D., Saijo, N., Watkins, C., Duffield, E. L., Armour, A. A., & Mok, T. S. K. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.8006 · Cited by 121
Kato, T., Hayama, S., Yamabuki, T., Ishikawa, N., Miyamoto, M., Ito, T., Tsuchiya, E., Kondo, S., Nakamura, Y., & Daigo, Y. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1297 · Cited by 118
Yamazaki, S., Sekine, I., Matsuno, Y., Takei, H., Yamamoto, N., Kunitoh, H., Ohe, Y., Tamura, T., Kodama, T., Asamura, H., et al. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2005.01.008 · Cited by 117
Schultz, R. M., Vj, C., Bewley, J. R., Roberts, E. F., Shih, C., & Dempsey, J. A. (1999) · PubMed · Cited by 93
O'Byrne, K. J., Bondarenko, I., Barrios, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.8007 · Cited by 92
Wislez, M., Antoine, M., Baudrin, L., Poulot, V., Neuville, A., Pradere, M., Longchampt, É., Isaac, S., Lebitasy, M.-P., & Cadranel, J. L. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.05.021 · Cited by 85
Ginsberg, M. S., Grewal, R. K., & Heelan, R. T. (2007) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2006.10.004 · Cited by 66
Structural and Functional Basis for Therapeutic Modulation of p53 Signaling
Bassett, E. A., Wang, W., Rastinejad, F., & El‐Deiry, W. S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1526 · Cited by 62
Hainaut, P. L. (2001) · Mutagenesis · doi:10.1093/mutage/16.6.551 · Cited by 58
Reasons for response differences seen in the V15-32, INTEREST and IPASS trials
Saijo, N., Takeuchi, M., & Kunitoh, H. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.37 · Cited by 25
Characterization of NSCLC patients responding to anti-IGF-IR therapy
Gualberto, A., Melvin, C. L., Dean, A., Ang, A. L., Reynolds, J. M., Lee, A., Terstappen, L. W. M. M., Haluska, P., Lipton, A., & Karp, D. D. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.8000 · Cited by 24
Self-citationShih, J., Yang, J. C., Su, W., Hsia, T., Tsai, C.-M., Chen, Y., Chang, H., Terlizzi, E., Shahidi, M., & Miller, V. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.8013 · Cited by 23
Molecular Origins of Lung Cancer: Prospects for Personalized Prevention and Therapy
Haura, E. B., Camidge, D. R., Reckamp, K. L., Chiappori, A., Johnson, F. M., Herbst, R. S., Wong, K., & Carbone, D. P. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181e2f682 · Cited by 19
Besse, B., Eaton, K. D., Soria, J., Lynch, T. J., Miller, V. A., Wong, K., Powell, C., Quinn, S., Zacharchuk, C., & Sequist, L. V. D. (2008) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(08)72135-9 · Cited by 16
Self-citationJohnson, M. L., Rizvi, N. A., Ginsberg, M. S., Miller, V. A., Kris, M. G., Pao, W. J., & Riely, G. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.8012 · Cited by 7
(2008) · Annals of Oncology · doi:10.1093/annonc/mdn503 · Cited by 3
Cited by
Non-small-cell lung cancers: a heterogeneous set of diseases
Chen, Z., Fillmore, C. M., Hammerman, P. S., Kim, C. F., & Wong, K.-K. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3775 · Cited by 1,942
Management of non-small-cell lung cancer: recent developments
Reck, M., Heigener, D. F., Mok, T., Soria, J.-C., & Rabe, K. F. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61502-0 · Cited by 714
Self-citationWarth, A., Muley, T., Meister, M., Stenzinger, A., Thomas, M., Schirmacher, P., Schnabel, P. A., Budczies, J., Hoffmann, H., & Weichert, W. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.2185 · Cited by 692
Wood, S. L., Pernemalm, M., Crosbie, P. A., & Whetton, A. D. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.10.001 · Cited by 485
Nishio, M., Barlesi, F., West, H., Ball, S., Bordoni, R., Cobo, M., Longeras, P. D., Goldschmidt, J., Novello, S., Orlandi, F., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.11.025 · Cited by 458
Metadata
- Authors
- Langer, C. J., Besse, B., Gualberto, A., Brambilla, E., & Soria, J.-C.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-12-20
- Volume
- 28
- Issue
- 36
- Pages
- 5311-5320
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1979101646
- Cited by
- 300
- References
- 92
- FWCI
- 16.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.